Related references
Note: Only part of the references are listed.Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity
Mona Meyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Hif-1α and Hif-2α differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells
Yi-Yang Hu et al.
CANCER LETTERS (2014)
Novel MSH6 Mutations in Treatment-Naive Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation
Stephanie A. Nguyen et al.
CLINICAL CANCER RESEARCH (2014)
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy
Michael Weller et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
MGMT testing-the challenges for biomarker-based glioma treatment
Wolfgang Wick et al.
NATURE REVIEWS NEUROLOGY (2014)
Lactate dehydrogenase A silencing in IDH mutant gliomas
Charles Chesnelong et al.
NEURO-ONCOLOGY (2014)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel et al.
SCIENCE (2014)
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis
Benedikt Wiestler et al.
ACTA NEUROPATHOLOGICA (2013)
Cancer heterogeneity: implications for targeted therapeutics
R. Fisher et al.
BRITISH JOURNAL OF CANCER (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Cancer heterogeneity-a multifaceted view
Felipe De Sousa E Melo et al.
EMBO REPORTS (2013)
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumour heterogeneity in the clinic
Philippe L. Bedard et al.
NATURE (2013)
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Andrea Sottoriva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma
Yoshinari Shinsato et al.
ONCOTARGET (2013)
Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor Heterogeneity
Suzanne E. Little et al.
CANCER RESEARCH (2012)
Intratumor Heterogeneity: Evolution through Space and Time
Charles Swanton
CANCER RESEARCH (2012)
Cancer in Light of Experimental Evolution
Kathleen Sprouffske et al.
CURRENT BIOLOGY (2012)
Epidermal growth factor receptor: a re-emerging target in glioblastoma
Monika E. Hegi et al.
CURRENT OPINION IN NEUROLOGY (2012)
Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions
Mital Patel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Assuring the quality of next-generation sequencing in clinical laboratory practice
Amy S. Gargis et al.
NATURE BIOTECHNOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Characterizing Mutational Heterogeneity in a Glioblastoma Patient with Double Recurrence
Gabrielle C. Nickel et al.
PLOS ONE (2012)
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
Nicholas J. Szerlip et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Yuchen Jiao et al.
ONCOTARGET (2012)
Intra-tumour heterogeneity: a looking glass for cancer?
Andriy Marusyk et al.
NATURE REVIEWS CANCER (2012)
O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction
Marta Brell et al.
BMC CANCER (2011)
Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Matija Snuderl et al.
CANCER CELL (2011)
Heterogeneity Maintenance in Glioblastoma: A Social Network
Rudy Bonavia et al.
CANCER RESEARCH (2011)
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
Joerg Felsberg et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
Jaime Gallego Perez-Larraya et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor heterogeneity: Causes and consequences
Andriy Marusyk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
M. Gerlinger et al.
BRITISH JOURNAL OF CANCER (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
A multigene predictor of outcome in glioblastoma
Howard Colman et al.
NEURO-ONCOLOGY (2010)
The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma
Andreas M. Stark et al.
NEUROLOGICAL RESEARCH (2010)
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
J. Dunn et al.
BRITISH JOURNAL OF CANCER (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Sibille Everhard et al.
NEURO-ONCOLOGY (2009)
A NEUROSURGEON'S GUIDE TO STEM CELLS, CANCER STEM CELLS, AND BRAIN TUMOR STEM CELLS
Samuel H. Cheshier et al.
NEUROSURGERY (2009)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
Eric Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers
Johan Skog et al.
NATURE CELL BIOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
Jonathon F. Parkinson et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions
J. Guy Lyons et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas
Eva M. Grasbon-Frodl et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
The 2007 WHO classification of tumours of the central nervous system (vol 114, pg 97, 2007)
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Incidence of gliomas by anatomic location
Suvi Larjavaara et al.
NEURO-ONCOLOGY (2007)
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E. Pelloski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A perivascular niche for brain tumor stem cells
Christopher Calabrese et al.
CANCER CELL (2007)
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Ulrich Herrlinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
W Stummer et al.
LANCET ONCOLOGY (2006)
Genetic clonal diversity predicts progression to esophageal adenocarcinoma
CC Maley et al.
NATURE GENETICS (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Mechanisms of disease: Neural stem cells and the origin of gliomas
N Sanai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Surgery for malignant gliomas: mechanistic reasoning and slippery statistics
P Mitchell et al.
LANCET NEUROLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
MGMT: Its role in cancer aetiology and cancer therapeutics
SL Gerson
NATURE REVIEWS CANCER (2004)
Genetic pathways to glioblastoma:: A population-based study
H Ohgaki et al.
CANCER RESEARCH (2004)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Treatment of malignant glioma: a problem beyond the margins of resection
A Giese et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2001)
Share Paper
